-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Asarwq38BW/unjAI93ABantFKWLK36DEOWPJO7t0u2M6tgQxdYWiGEZ4/Gapsk2b
 r0AJJKJ4rpW0xajWSkLYCg==

<SEC-DOCUMENT>0000950144-08-008553.txt : 20081113
<SEC-HEADER>0000950144-08-008553.hdr.sgml : 20081113
<ACCEPTANCE-DATETIME>20081113085733
ACCESSION NUMBER:		0000950144-08-008553
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20081110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20081113
DATE AS OF CHANGE:		20081113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		081182873

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g16640e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): November&nbsp;10, 2008</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(State or other jurisdiction of</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(IRS Employee Identification No.)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>incorporation or organization)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2 below).
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR
240.13(e)-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!--TOC-->
<!--/TOC-->





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>
<!-- link1 "Item&nbsp;2.02 Results of Operations and Financial Condition" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;10, 2008 we issued a press release reporting our quarterly results of operations
for the period ended September&nbsp;30, 2008. A copy of the press release is attached to this Current
Report.
</DIV>

<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press Release
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">&nbsp;2 of 3
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: November&nbsp;13, 2008
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">&nbsp;3 of 3
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g16640exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g16640g1664001.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">Contact:<BR>
Melanie Nimrodi, Media Contact<BR>
312.546.3508<BR>
<U>mnimrodi@frbir.com</U><BR>
At the Company:<BR>
Robert McNally / Jennifer Nelms<BR>
404.727.0971

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">FOR IMMEDIATE RELEASE
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>GEOVAX LABS, INC. ANNOUNCES THIRD QUARTER 2008 FINANCIAL<BR>
RESULTS AND PROVIDES OPERATIONAL UPDATE</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ATLANTA, November&nbsp;10, 2008 &#151; </B>GeoVax Labs, Inc. (OTCBB: GOVX) (&#147;GeoVax&#148; or &#147;the Company&#148;), a
biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human
Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2008
financial results and provided an operational update.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Robert McNally, GeoVax&#146;s President and CEO, commented, &#147;We are very pleased with the progress we&#146;ve
made during the third quarter of 2008 and for the year so far, as we&#146;ve taken steps to address both
short-term and long-term goals. We made a shipment of the vaccine to the HIV Vaccine Trials Network
during October, which is a significant step in preparation for the largest clinical trial yet to be
undertaken by GeoVax and we look forward to HVTN&#146;s initiation of the Phase 2a trial later this
year. We are also nearing completion of a license with Vivalis S.A., a French biopharmaceutical
company, for manufacturing platform technology for the MVA portion of our vaccine that we
anticipate will significantly improve the long-term production capabilities for the vaccine.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Financial Results for the Three Months and Nine Months Ended September&nbsp;30, 2008</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company recorded a net loss of $722,108 for the three months ended September&nbsp;30, 2008, compared
to $1,165,519 for the same period in 2007. For the nine months ended September&nbsp;30, 2008, the
Company&#146;s net loss was $2,688,970 as compared to $3,085,926 in 2007. Net losses for 2008 were
partially offset by grant revenues of $1,322,502 and $2,298,571 for the three month and nine month
periods, respectively, related to the Company&#146;s grant from the National Institutes of Health (NIH)
in support of its HIV/AIDS vaccine development activities. As of September&nbsp;30, 2008, the Company
reported cash balances totaling $2,784,706.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Summarized financial information is attached. Further information concerning the Company&#146;s
financial position and results of operations are included in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Third Quarter Operational Highlights:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On October&nbsp;22, 2008, Dr.&nbsp;Robert McNally, GeoVax&#146;s President and CEO, was the featured
interview on the Wall St. Network&#146;s 3-Minute Press Show, a daily program that features
in-depth interviews with public company executives. The interview may be viewed in its
entirety at
<U>www.tv.wallst.net/r/3-minute-press/Bob-McNally-GOVX-BB/306/1207</U>.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On October&nbsp;31, 2008, an additional interview with Dr.&nbsp;McNally was published by <I>CEOCFO
Interviews &#038; News </I>(<U>www.ceocfointerviews.com</U>). Also, GeoVax was prominently featured in
a special Biotechnology supplement to the November issue of <I>Harvard Business Review, </I>sponsored
by the Michigan Economic Development Corp (MEDC<I>)</I>.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On October&nbsp;20, 2008, GeoVax announced shipment of both components (DNA and MVA) of its AIDS
vaccine to the HIV Vaccine Trials Network (HVTN)&nbsp;pharmacy, for use in the upcoming Phase 2a
human clinical trial. GeoVax also announced the submission of a Biological Master File
Amendment to the U.S. Food and Drug Administration (FDA)&nbsp;for review of the manufacturing data
for the product shipped to HVTN. The Phase 2a trial will be conducted by the HVTN and will
involve 225 healthy volunteers from the United States and South America. The trial will
further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine
administered prior to infection with the HIV virus) and will broaden the base of safety and
immunogenicity data for the full dose of the GeoVax AIDS vaccine. This trial will serve as a
major milestone, as the Phase 2a trial is the most advanced trial to-date for GeoVax. HVTN and
the clinical trial sites are moving forward with the administrative steps necessary to prepare
for commencement of the Phase 2a trial, which GeoVax expects to begin before the end of the
year.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In October&nbsp;2008, GeoVax announced that its company information is now available via
Standard and Poor&#146;s Market Access Program, an information distribution service that enables
subscribing publicly-traded companies to have their company information disseminated to users
of Standard and Poor&#146;s Advisor Insight. GeoVax&#146;s company information is also available via
Standard &#038; Poor&#146;s Stock Guide database, which is distributed electronically to virtually all
major quote vendors. These services will help GeoVax comply with numerous state &#147;Blue Sky&#148;
laws to ensure that its stock is made available to the broadest possible investor base.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On October&nbsp;15, 2008, GeoVax presented data on its Phase 1 AIDS vaccine trial (HVTN 065) at
the <I>AIDS Vaccine 2008 </I>conference, in Cape Town, South Africa. The presentation, entitled &#147;<I>Two
HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen
Administered to Healthy Seronegative Adults (HVTN 065)</I>,&#148; was given by Dr.&nbsp;Paul A. Goepfert,
M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University
of Alabama. Dr.&nbsp;Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the
GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune
responses) at both low (1/10th) dose and full doses. Other highlights of the presentation
included:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the
majority of trial participants.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>80&nbsp;percent of both the low and full dose trial participants responded to the vaccine
which stimulated anti-HIV T-cell (white blood cell) and antibody responses.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>More volunteers had antibody responses to the full dose than to the 1/10th dose
vaccine, whereas response rates for T cells were similar for the 1/10th and full dose.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Two DNA primes were more effective than one DNA prime or no DNA primes at eliciting T
cell responses.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The 2nd MVA vaccination positively increased CD8 T cell and antibody responses.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Dr.&nbsp;Harriet Robinson, the developer of the vaccine and GeoVax&#146;s Vice President of Research and
Development, also presented these same results at the <I>Viral Vector Vaccines 2008 </I>meeting, at the
Wellcome Trust Conference Center near Cambridge, UK, on September&nbsp;28, 2008.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In August&nbsp;2008, GeoVax announced the appointment of Mr.&nbsp;Peter Tsolinas to its Board of
Directors. Mr.&nbsp;Tsolinas also was subsequently appointed to membership on GeoVax&#146;s Audit
Committee and Compensation Committee. Mr.&nbsp;Tsolinas currently serves as Chairman and CEO of TMA
Group Development Corp., a Chicago-based real estate, architectural and development firm.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In July&nbsp;2008, GeoVax and Vivalis S.A., a French biopharmaceutical company that provides
innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines
and proteins, jointly announced the signing of a letter of intent for joint collaboration and
commercial license on the use of Vivalis&#146; EBx<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>technology, to manufacture the MVA
component of GeoVax&#146;s HIV-1 vaccine. The breakthrough manufacturing technology developed by
Vivalis, through further development collaboration with GeoVax, will create a new standard for
manufacture of the MVA component of GeoVax&#146;s HIV/AIDS vaccine. Vivalis&#146; EBx<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
</SUP>manufacturing platform, with its increased effectiveness, superior quality and
reliability, is expected to better provide for MVA vaccine product availability in ample
quantities to meet sizeable demand and at a lesser cost. Vivalis&#146; vaccine manufacturing
technology is based on a duck embryonic stem cell substrate platform. Specifically, the
EB66<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>cell line provides continuous growth from a fully characterized frozen cell
bank, without necessitating fertilized embryo extraction and processing, as with present
chicken cell based technologies. Furthermore, the EB66<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>cell line can be grown in
suspension (without the cells attached to the surface of the growth vessel) and can be scaled
up for growth in large bioreactors for commercial-scale production of the MVA viral vaccine.
The details of the final license agreement between the parties are being negotiated and GeoVax
expects the final agreement to be executed before the end of the year.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;On the financing front,&#148; Dr.&nbsp;McNally noted, &#147;we are pleased with the financing strategy provided
by the $10&nbsp;million common stock purchase agreement with Fusion Capital Fund II, LLC, from which we
are drawing in a judicious manner, and we are also benefiting greatly from government support in
two ways &#151; from both the 5&nbsp;year $15&nbsp;million grant (approximately $3&nbsp;million awarded annually)
initially awarded in October&nbsp;2007 by the National Institutes of Health, and also from ongoing
clinical trial support provided by the HVTN.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;McNally concluded, &#147;We believe we are well-positioned for success in 2009 and beyond, with our
preventative vaccine beginning Phase 2 human testing and our therapeutic vaccine trial in the
planning stage. Based on highly promising results in preclinical non-human primate studies
conducted by Dr.&nbsp;Rama Amara at Emory University, we are eager to launch a therapeutic Phase 1/2
human clinical trial in individuals already infected with HIV to investigate the use of our vaccine
as a therapeutic treatment to control HIV-virus levels. We expect this trial may start in mid-2009
and we will report on the development of this program as we conclude plans with our trial sponsor.&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.<BR>
Condensed Consolidated Statements of Operations Information<BR>
(amounts in thousands, except per share data)<BR>
(unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Three Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Nine Months Ended</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">September 30,</TD>
    <TD style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">September 30,</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2008</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2007</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2008</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2007</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,322</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,298</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,362</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">360</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,725</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,273</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">699</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">815</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,322</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,865</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,175</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,047</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,138</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(722</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(1,166</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(2,689</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(3,086</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" nowrap align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" nowrap align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.<BR>
Condensed Consolidated Balance Sheet Information<BR>
(amounts in thousands)<BR>
(unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Sep. 30,</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Dec. 31,</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2008</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2007</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,785</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,990</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">578</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,041</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,363</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,031</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">368</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">140</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,858</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,246</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">516</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">598</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,342</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,648</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,858</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,246</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Shares Outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">743,415</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">731,628</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About GeoVax Labs, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s HIV/AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax HIV/AIDS vaccines are designed for use in uninfected people to prevent
Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person
ever become infected. GeoVax HIV/AIDS vaccines also may be effective as therapeutics (treatment of
people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected
individuals are in the planning stage.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s core HIV/AIDS vaccine technologies were developed through a collaboration of colleagues at
Emory University&#146;s Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease
Control and Prevention (CDC)&nbsp;and the GeoVax team.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV/AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by <B>NIAID</B>, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant
awarded in late 2007. www.geovax.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Safe Harbor Statement: </I></B><I>All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions as of the
date of this press release and are subject to numerous risks and uncertainties which could cause
actual results to differ materially from those described in the forward-looking statements. Risks
and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture
these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be
determined to be safe for use in humans, GeoVax&#146;s vaccines will be effective in preventing AIDS in
humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed,
GeoVax can raise the required capital to complete development of its vaccines, there is development
of competitive products that may be more effective or easier to use than GeoVax&#146;s products, and
other factors over which GeoVax has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. Certain matters discussed in this news
release are forward looking statements involving certain risks and uncertainties including, without
limitations, risks detailed in the Companies Securities and Exchange Commission filings and reports</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g16640g1664001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16640g1664001.gif
M1TE&.#EAWP`D`.8``)BUQ:>SNK7*UJ.ZR)2JNLC=Y65ZC/G\_2`Y6X:;KE!D
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MM)7`SRI.>7:#B_[\_6:!D/C[_=3H[O[]_E-WGRM'9,O/T?WZ_-OGYB9);U!U
MD_G\^OO\_3%2;?O]_E)OD3Q>>4UPA_;[_?#O\?G[^_S^_"`]9_7W^/S[^_[^
M_O[____^_O[^_____O[__G&4K>ON\./?X[3#PR9.9IRLL____R'Y!```````
M+`````#?`"0```?_@'^"@X2%AH>(B8J+B'6"<T9-)"5LCHR7F)F:FYR=GI^@
MH81T=GQG+2@WHJNLK:ZOFG1T@B.U:&@';!Y&O%"^4!W!PAO$&S>\'AX'M[>U
M(V8+-3M-:'.$EK#9VMNKLY=T:&P0+B)\`0$H!#-`"PM$1"GQ._/T$_$I-C8+
M"3,R?GXHCHC0(::#`@P"JED;U(6;PX<0%S4<-&+.B"(5/N#X0<&*@Q1DIJBY
MD@,.`@0U:B1)\F6(RS,P&\B<2?/,D"5+OM1`@*'GF2H1QFCP<>('CB`O-GBH
M]@=;Q*=0MXV`<F+!A"E.:%`9(D%"CC%C<N1``,<)$0(#(A@]^N%#D!(O_^+*
MG5NB1)"V.#:*.!(@000G.8"HX/G%!`<-%VSXZ8"F8M3'D#<M%-3DR0`'-AK4
M6%)C3$HX2:C0L#!A@8,!)YZL4(;&#BL[4P4@:""`0`(#*CB82%(#`Y4),PA0
M>'"CL>O(R)./0..A`I\>6#2HN<FYQI<S%R8(%X&#!0,(6]"`FC/Y>"$D$+0L
MN0#^1@4A+'`(`+!@Q_0D+118R!"@A)$#CB4G($1SO-#7#@UPUD=*-31`A@TR
M'"%&&V;`8I$W%IDGB!0%G"$!`>(58@<:6U0@0E\9<#!$#E=XL0`!'[`QX(RP
MU')`"(,M,09.FR%@P@(/M';<&TTY4L>12'XRQ_\!6WB@82$C.(!`$BY@,@<:
M4)!@P4D[-0#`"FR@<8<4-):YR8AH&$'"!#340!))*G$0``X55&,';&QP<0(0
M\TPPP06)%>")'44<8<`$+XPPIB$=3("`"C!8::,+`LR@0I<[@'##"'B,8N:G
MB*"Q000*(+`$BUXAH```&P`HRPB.',"%!7"8=!(<*9U$1HB2S>&""0@08,0=
M=QAR0F$59-(I'2/\,<(!1CQ0A1HI<3!#!P=0Y`VHH,JB0P8)BI4#3A<,\`$,
MQQ7[AQT>1'"!FRHD,,"\)]0+0`+-+D(>(<4N"4`.:3PPAQ3;TC%''C48<(!3
MAF"#Q[9_W&%1!SH,D$;_#E3L$,(!UM@!,;=ETG&`%CIY]=47!@3Q9+%2V/'#
M%)Y5P4(<ALBQQV2)[#N(NDA4X`05`EA3,!13+`%`4XHXM6T=75@B<@@:Y"`!
M&5R,,!'(G]+A@A8U##%&5TLDD0`;'T=\QQM&:+#$&4_@_`FQZC)EA@TU+"`C
M(5LXL`0'&S0LR)'\&O+QDB%PT*``L&+]Z08JP-$5')ZI(``$(Y1-[!81?)&$
M`P>HB\ERR]RRL[-I&L%&11\,H4$!"]W1,[5,&''+`<J,L,5_5]+N@46"P.;!
M#5M4/@AY6_S@Q*,//*EX<G.(@,`574DP1!)B;)$MPX\P7H,64,B!?2$&'_`!
M_PI,9."`#YOF^X>L!,#C@`[-[@"'!48(<O8`.9P!0IX$&$":`"A00`8Z,``%
M*(`)?:-%`7:@@1XHH7*R&`0:0D`%!!QM>30:00`0(#4)X.H"%?K;'R+H+(M4
M0`U4&``:)K*D)K%A"S`4#QI@<`0%M"`)-Z&!'^IT)#V`P`!<N0(5%'"$"A!@
M;0^@Q0TN(($+E(`"%OB"!,!"@Q2<X0L@>`$`U/"%`7C@#P4B`APNP((BP`:"
M@XC#NX"`!`S."`THX&!8<F(%P7FC,7,(`A6<\`)B"8(!/P!!!`89`0$TX0YH
M`$$2I.:$-30`#DN8@0>R4`<4J`$!?7#"%!K0!PS,`/\'',"`%6+%A2O`@0`"
M,.40IN"%XYV,`G_P0`+*$K0#Y`%C"4E$'2)P!2"X<49S^``.NV+*"$RD;'-`
MPAM2-X4D%NL!6R++K<IBA!"8``,RT$,7YK`%,&S%`5!XPA<PP`08U`$-%4#!
M@DY0A1IHH`UU*$(<:>`##2`@!8D:`1L&T(`<)`&6?X!!!C!PAA,`8)P`4)\A
M+%*`!OC@EP.ZD@$0T)6Q`.![@D"",H.P2F?^00@*X(!(#<@!.%QA`P1`0`9"
M>*$9(*`%36`"'%3P@H%9Q`@SJ,$$%/F%$-2!`8,9P$$ML`$SD&<.'EB`9P#Z
M!S&$T@D-0(`6-N`V0BS)*@G_A"CS7K"`6HF%!GJ8`QVNQJ\1-`&%`,C6']H@
M!!B6`1<%2,(80I`&!/C`:ENH#`D`<`8,D*!Q^+)#&[L0AA>H00-/<``&@'``
M$+3`!`](01)0@(8LJ&L$/TB0`(Z#AA-PP"L7T$$(#S$"#_R`"1_@E58C`YL.
M:($*CH.#'RA7U8C9`0H6J,$%FM"L+&3!?H(0YA4H0(,<1$$0+R""!J:@@3X@
M@`0*R`$**E*1+F1A`QHP@0Z$J88*2(D)-TC!$"(PARSD*YB:/<X<.F`#.$CW
M!K45Q!;$$``E'$!Y6O5&V;@!@P%<@`H2.`,3=&"'JA(+#118PA`<\,5';*L`
M+*(K_QP>^@<18$`--%!#`U3P``Z(K<!EF$/33LB!#Q1A`C7(@P:^4`!;UF``
M(\B"-[KP@S/D(`+>.,``BEN6`:C5$#!X@0Z*`!&,MD*_48$$/\>E!A)<KPY2
M(%/$6C:8,_A`K1`KP!*NL`(II<`-?P"##(2P!Q:P0`]HP,*C.F"U/V0A#@08
MPP3Z)H`EU$H%4+`#`-:S@H$UY0`SV)$`!D&",]0@#3`[`PDL`;<_=*$-<="0
MD2.S7T8P[1-W^H-J%0&Z'^P&`19XP!::AH8V6J,.=I#!%Q!P@:HYHUDC*$!+
MJ$)0$J!3#$0"XY4"@($OG,`#9D###0H-!TG^P05?&)?=*O]L@B%8`0K+&`$7
M5)"#(0!T!`#HS0`V:+2EF$UB1V*6,QA1:7*C:1L>>U5\8R$RV"R"%"-XPQ9>
M0`$F<"!>(6B-($BQOB?LH`9PX,`$$N"`@A,@#UN.`PP(T+4+)(``$"<`"E#P
M`B/8X(8#Q\P96%T!1;&AJTUNUA8`,(0:6,`!";!!F\;PS_6=8`@F2(4'"-"`
M+SA``"$H@1XH!`,*)`H-.J"`*A1A!QYD4Q.$"X`?&'")$<0@!@I%!!TZ(*$M
M/!':^+V$:Q@@`Q@4X099?T0RB76D$=P@!`#(`'_`X(+B*,0(7)B`!JX0%I-)
MC45H;H+*P>85Z7UA!D5@0`(4D`3_L*GA`@48090Q.P0M?/%(3:B"$UI0=RJD
M@09)&,`&?I"&(20@4G.XP0Q:,(4$G.`!'$.G`OR`3@,P805&\("-CK&<7:`!
M`EC0PU*6$K[B^`YW=8BU`0R@!3"\@0VR\]TN9!\.-)RC#,K8U)5V`4-BT<&Q
M%(""`SCP`".01_:Z6\8-LM4%-MR`#4M:2G'FH`0L0.`<4'!2"\MM"#0P@"\+
M0$$!XI\OFPT@#U[@!600@&2`:&!0"UL@`@YP`6F0!@)(!FN@!5Q@!V8@!`ZP
M`Q>P`#]0/X60`12@4&C@`@2P`V1`!`)0`2=@`4!@!3M@`:_7+(X0!S$@!)L&
M`PJP`)W5_P)/```V@`(0<``"``0S``%-0``+@`,%``(D,``OD`"I=0!'D`$X
M<``PD``9D&^.,`,6P&:AYP`+(`)V\`(#0```<`)0\``#X`(@4`%!4"\ST'$O
M$!P%H`,:]0<`T`(LL`(&H`!-$`$\X`814`$E$`$`\`--``0/Q749<&4X4!0+
MP&9!$`(18`(J$`$44`0)&`11APF;%P`B\`)MP`,A5%K$``$=``'%P`.$@"4;
ML`*N^(H-IFDKT`1&L(E_``%F)"('L`$_^#<P@(JN2%5N\S'Q9``I<(@HL`(H
MD`)J<`(@H`):D`$%H``&D`$"D`$)(`"KIP(&\``"D`8VP`$A$/\`:<`$?%`&
M@G`")C``#%`$?$($&;`!GI4!]O8`**`%.J`!00``"F`#:H`%%8`%U;@&`4`\
M>1!S)_"/`C`!0:8").``:V`#*N``R^4&);``6M``8K!]"\`!`P`%!%<%H`8`
M'%`!(6``0I`)PD,+Y'$`11"*9K`4CD$*)&0(!68PMM`85N4,564P<W`<E@`;
M.%,'E&01M6`-?K1OA5`'MK0#$3`!'?`!&9`'#4``$Z!Y'J`/%>`!#]`"1X`"
M6Q@$'!`!&N`%>=`"?K!CK-(%32./)F`!.G`&1)`'*O`$!I``'5``&A`"%O`#
M):`!4;`?*[`#"H`"!M`!*Z``L!1Z3J#_!10P``AP`IAQ=AP0!6L`!%$P!00`
M-3=P`C9`!`B@`Z6Q`E60`%KR!%&0!`*P`B90``;@![;X#8<0=H<P:8-0;O1W
M#8D`-QB%;30P`4<``Q:``E;@4%I``$VP`7X2!!OP!`AP6@F`!@)@`60)`(-4
M`DV0;2'0+##`!4UP`:M#`U80`4KHE6RP`3M@`P2P`0)@`%&PCC>@`?EG`"O@
M`R;0!*[Q*R#@`0+``5R0`$!PB!8``LWX0TUP`AIC`0-0!6/`!5H@`$:@!0&P
M8U`P`PWP!%!P`7E@`"Y`FQ:R;E*W"+;)",7B.830!79``4F@!7H0!X>R`]H5
M`)0H`];$`0G`_P<MP`4&@`)UD`!XF0!D,`,@$`),,`$MD%IS@`/0:`(.``$J
M,`%`4!08D%IL0`0<0`DRP`0AT`(_``$M``!/`(T3P#>.``8MP!A^8`$W0`"C
MH0`)@`(<\`-'$#M^,`,Z8`$V8`$T4`(&\`$;H``BT)$>$`!B`P55L`0!L`4@
MNEJPX`@NX`<BX`9H``9^0`$!H`=ZX`<R\`-%$``RP`="X`=0`*H5A@-H(`;^
M(`8,X`<$<`3U8P=<EY8U)69^\`$N$``PP"P@D*@C``9@4`)^T*(HX`+RB`)5
M8`%;X`@,$`!%,`(XP`=F`*P!0`'Q<:DL``8'``8?X`%\<2)Z0`%MT(NI;;`7
MCU:I4+``9\``B\JHHE`VLQ!ULR`+Y'$D=T)6.^,Y_&8(G8(TF08QC;&2:&`)
M!]`%`:`;"A`$86!9B/`L^W9J3?%;NG8EYV0)#*,$U)A$BI.44%%IM26O<T"O
M=L`PLY`D8)2;.8,S^@9&60`!\<$`U66B5F4-E;,0ER9V\XHTA\`#WH&.@Q`(
"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
